Evelyne Nguyen

Charles River prides itself on solving the most complex bioanalytical challenges. Philippe Ancian, Director of Biomarkers, shares how his team recently validated a highly specialized CAR-T assay, enabling clients to quantify viral vectors with speed, precision, and scientific rigor. This milestone didn’t just advance science – it ensures critical therapies reach patients faster. That’s the impact of true biomarker expertise. 👉 Discover how our biomarker teams deliver clarity, speed, and results: https://okt.to/Oc5Glg #biomarkers #bioanalytical

168

5 Kommentare

We are happy to announce the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.  The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in the country. To know more about this announcement, please visit https://bit.ly/4mZHtC4

447

6 Kommentare

Good news for Bioxodes and its treatment for haemorrhagic stroke. Following promising results from the Phase 2a clinical trial, Bioxodes can move on to a new phase and aims to bring the product to market before 2030. Marc Dechamps, Chief Executive Officer of Bioxodes: “We are in discussions with prospective investors and partners to support the launch of a potentially registrational Phase 2b trial of BIOX-101 to treat intracerebral hemorrhage. Given the high unmet medical need in ICH and Orphan Drug Designations for BIOX-101 in both the U.S. and EU, we believe this breakthrough therapeutic candidate can come to market as early as 2030.” 👉 Read the full release: https://lnkd.in/eyXTrXY9 👉 Read the full article: https://lnkd.in/e3EprXvY

190

9 Kommentare

In June, our EVP, Discovery Science, Markus Haeberlein, chaired Hanson Wade’s 5th Annual Induced Proximity-Based Drug Discovery Summit – an event which aims to expand the frontier of #TPD and other proximity-based modalities. At Parabilis, we are expanding those frontiers by engineering TPD drugs that can do things that are not possible with traditional small molecules. Our Helicon degraders can engage with highly challenging intracellular targets, thanks to their ability to penetrate cells and bind relatively flat protein surfaces. Learn more about how we apply our Helicon degraders to eliminate traditionally undruggable proteins: https://lnkd.in/eWzFMkt9 #DrugDiscovery #ProteinDegradation #TPDsummit #InducedProximity 

72

We're combining our AI expertise with NeoGenomics Laboratories' vast pathology dataset and FRANCE TISSUE BANK's high-quality samples to tackle one of precision oncology's biggest challenges: consistent IHC interpretation. We’ll be developing a foundation model exclusively trained on immunohistochemistry (IHC) images to enable more precise biomarker quantification across varied clinical settings. This collaboration aims to help unlock more standardized and quantitative diagnostics, potentially improving patient access to targeted therapies. Read more about our approach to an IHC foundation model: https://lnkd.in/ezUY3hbT #PrecisionMedicine #DigitalPathology #CancerDiagnostics

97

Exciting Milestone for SOFIE Biosciences 🚀 We are proud to share that following a successful End of Phase 2 (EOP2) meeting with the FDA, we are advancing two Phase 3 clinical trials for [18F] FAPI-74, our fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP). This milestone builds on the favorable results of our Phase 2 multicenter study in gastrointestinal cancers, where [18F]FAPI-74 demonstrated: ✓100% positive predictive value in detecting FAP-expressing cells ✓94% positive predictive value in detecting GI oncologic malignancies With FDA guidance on study design and endpoints, we are preparing to launch: FAPI-GO – focused on gastroesophageal cancers FAPI-PRO – focused on pancreatic ductal adenocarcinomas These pivotal studies bring us one step closer to establishing FAPI PET/CT as a transformative tool in precision oncology, addressing areas of significant unmet need. We are grateful to our clinical partners, collaborators, and team members whose dedication have made this achievement possible. Read our press release here: https://lnkd.in/eWHgRigN Learn more about SOFIE’s vision to improve patient outcomes in molecular diagnostics and therapeutics: https://sofie.com For more information about FAPI: [email protected] #precisionmedicine #radiopharmaceuticals #fapiforward #redefiningdetection #fromstarttoclinic

164

8 Kommentare

🎙️ #Sharing_Knowledge Podcast | Episode 3 "Go Where You Make an Impact" In this episode, we host Dr. Hajed Bin Hajed Hashan, Executive Director of Scientific Affairs and Business Development at #SPIMACO, who shares his vision on the importance of scientific innovation and continuous development, and how research and practical experience enhance the quality of pharmaceutical products while creating a positive impact in the healthcare industry. He also discusses the significance of technology transfer and integrating global knowledge to improve operational efficiency and advance pharmaceutical solutions. 🎧 Tune in now and share your thoughts in the comments! 📎 Episode link: https://lnkd.in/dPW9zp4T

132

8 Kommentare

Excited to share that several of our Iambic Therapeutics colleagues will present at next week’s High Throughput Chemistry and Chemical Biology Gordon Research Conference, which is focused on generative AI for drug discovery. They will highlight the automation powering the integrated AI and high-throughput experimentation platform behind our clinical pipeline — as well as advances to NeuralPLexer, Iambic’s leading model for protein-ligand structure prediction. Talks and poster presentations by our scientists and machine learning innovators include: Joseph Dennis, Principal Scientist, Medicinal Chemistry Talk: Leveraging Automation in a High-Throughput Experimentation Platform to Fuel ML-Driven Drug Discovery Mia A. Rosenfeld, PhD, Machine Learning Scientist Talk: NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models James Garrafa-Luna, Associate Scientist II, High-Throughput Experimentation Poster: Empowering Iambic’s High-Throughput Experimentation Platform through Software and Reaction Optimization A shout-out also to Alexander Buitrago Santanilla, PhD., Iambic’s Associate Director, High-Throughput Experimentation, for his work as Vice-Chair of this year’s HTCCB event. Learn more about the conference here: https://lnkd.in/eXv3AsuD #AI #DrugDiscovery #HighThroughputChemistry #MachineLearning

106

2 Kommentare

CDMO Weekly: From Strategic Partnerships to Major Expansions — 23 Key Moves Celonic Group and CARBOGEN AMCIS form alliance for end-to-end ADC development. VectorBuilder unveils miniVec plasmid system for safer, scalable genetic medicine manufacturing. Sai Life Sciences Ltd launches integrated CMC partnership with Agility Life Sciences and Centrix Pharma Solutions. Recipharm announces Cuxhaven facility as analytical services centre of excellence. Lisata Therapeutics, Inc. partners with Catalent to integrate Certepetide into ADCs. Piramal Pharma Solutions introduces PODs system to enhance project delivery in Canada. Kincell Bio partners with Moonlight Bio to advance T cell therapy into clinical trials. Bora Pharmaceuticals adds high-potency liquid-filled capsule capability at Taiwan site. OXB acquires viral vector facility in North Carolina for $4.5M. BBG Advanced Therapies partners with CELLforCURE by Seqens to expand global ATMP manufacturing. Mycenax Biotech Inc. partners with Alfresa, Kidswell Bio Corporation, and Chiome Bioscience for Japanese CDMO expansion. Kincell Bio partners with Duke University to advance cell and gene therapy. Made Scientific and Streamline Bio validate AI-Driven robotics for cell therapy manufacturing. Matica Biotechnology, Inc. secures 10+ new manufacturing projects by mid-2025. Scinai Immunotherapeutics Ltd. secures $246K grant to expand CDMO fill-and-finish capacity. ROVI Pharmaceutical Company rebrands CDMO unit as ROIS and expands into U.S. with Phoenix facility. Rentschler Biopharma expands CDMO services across Japan and South Korea. Mytos launches automated CDMO offering for scalable stem cell therapy manufacturing. Lonza launches TheraPEAK® products to boost cell and gene therapy manufacturing. Vaxcyte signs $1 billion fill-finish manufacturing deal with Thermo Fisher Scientific. XenoSTART and Minerva Imaging unite for integrated radiopharmaceutical drug development. Delpharm is expanding sterile manufacturing capacity at Saint-Rémy Site. Mabion S.A. appoints Gregor Kawaletz as CEO. 𝐂𝐃𝐌𝐎 𝐍𝐞𝐰𝐬 𝐀𝐧𝐚𝐥𝐲𝐬𝐞𝐝 UPDATED DAILY: Download our tracker of CDMO announcements, investments and partnerships. https://lnkd.in/gekf-bpK #CDMO #Pharma #ContractManufacturing

38

25 Kommentare